Correlation Between Sino Biopharmaceutica and Enlivex Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sino Biopharmaceutica and Enlivex Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sino Biopharmaceutica and Enlivex Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sino Biopharmaceutical Ltd and Enlivex Therapeutics, you can compare the effects of market volatilities on Sino Biopharmaceutica and Enlivex Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sino Biopharmaceutica with a short position of Enlivex Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sino Biopharmaceutica and Enlivex Therapeutics.

Diversification Opportunities for Sino Biopharmaceutica and Enlivex Therapeutics

0.33
  Correlation Coefficient

Weak diversification

The 3 months correlation between Sino and Enlivex is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Sino Biopharmaceutical Ltd and Enlivex Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enlivex Therapeutics and Sino Biopharmaceutica is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sino Biopharmaceutical Ltd are associated (or correlated) with Enlivex Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enlivex Therapeutics has no effect on the direction of Sino Biopharmaceutica i.e., Sino Biopharmaceutica and Enlivex Therapeutics go up and down completely randomly.

Pair Corralation between Sino Biopharmaceutica and Enlivex Therapeutics

Assuming the 90 days horizon Sino Biopharmaceutical Ltd is expected to under-perform the Enlivex Therapeutics. But the pink sheet apears to be less risky and, when comparing its historical volatility, Sino Biopharmaceutical Ltd is 1.47 times less risky than Enlivex Therapeutics. The pink sheet trades about -0.02 of its potential returns per unit of risk. The Enlivex Therapeutics is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  124.00  in Enlivex Therapeutics on December 2, 2024 and sell it today you would lose (4.00) from holding Enlivex Therapeutics or give up 3.23% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy93.02%
ValuesDaily Returns

Sino Biopharmaceutical Ltd  vs.  Enlivex Therapeutics

 Performance 
       Timeline  
Sino Biopharmaceutical 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Sino Biopharmaceutical Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.
Enlivex Therapeutics 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Enlivex Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Enlivex Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Sino Biopharmaceutica and Enlivex Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sino Biopharmaceutica and Enlivex Therapeutics

The main advantage of trading using opposite Sino Biopharmaceutica and Enlivex Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sino Biopharmaceutica position performs unexpectedly, Enlivex Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enlivex Therapeutics will offset losses from the drop in Enlivex Therapeutics' long position.
The idea behind Sino Biopharmaceutical Ltd and Enlivex Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Transaction History
View history of all your transactions and understand their impact on performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Valuation
Check real value of public entities based on technical and fundamental data